[Selection of mutant rifampin-resistant Staphylococcus aureus during the therapeutic use of this antibiotic in combinations. 3 cases].
Selection of rifampicin-resistant Staphylococcus aureus has been described in vitro and in vivo when this compound is given as monotherapy or orally. That this occurrence may be prevented by combination-antibiotic therapy is generally accepted. We report three cases of serious staphylococcal infection treated by a synergic association of rifampicin with either an aminoglycoside or vancomycin. Therapy failed as a result of selection of the same rifampicin-resistant Staphylococcus aureus (serotype and lysotype). These observations may be explained by insufficient diffusion or inactivation of the other antibiotic in the infection site.
D000328:Adult; D000368:Aged; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D012293:Rifampin / Q000378:metabolism / Q000627:therapeutic use*; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000235:genetics
D012293:Rifampin
Sélection de Staphylococcus aureus mutants résistants à la rifampicine lors de l'utilisation de cet antibiotique en association. Trois observations.